Safety and effectiveness of tumor-ablative chemotherapy combined with low intensity modified conditioning regimen for 30 patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation.
10.7534/j.issn.1009-2137.2014.04.030
- Author:
Rong-Mu LUO
1
;
Wan-ming DA
2
;
Bo HU
1
;
Ying-Jian SI
1
;
Xiao-Mei ZHANG
1
;
Zhen-Lan DU
1
;
Quan-Hua LIU
1
;
Ya WANG
1
;
Yan YUE
1
;
Wei CHEN
1
Author Information
1. Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
2. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: Dwanming@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
adverse effects;
therapeutic use;
Child;
Child, Preschool;
Female;
Hematologic Neoplasms;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
methods;
Humans;
Infant;
Male;
Middle Aged;
Retrospective Studies;
Transplantation Conditioning;
adverse effects;
methods;
Transplantation, Homologous;
adverse effects;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(4):1047-1052
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the safety and effectiveness of tumor-ablative Chemotherapy combined with low intensity conditioning regiment BUCy/TBICy for patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical data of 30 patients with hematologic malignancies received above-mentioned therapeutic method from January 2012 to January 2013 was analyzed retrospectively, and the engraftment, GVHD, infection, conditioning-related toxicity, relapse and survival rates were evaluated. All the patients signed the informed consent before transplantation. The median follow-up duration was 20.5 (16.3-27.3) months. The results indicated that all the patients had been engrafted successfully. One year overall survival (OS) and disease-free survival (DFS) rates were 93.3% and 83.3% respectively. No conditioning-related toxicity occurred. The incidences of II-IV grade aGVHD was 37.9%, among which incidence of III-IV grade aGVHD was 3.4%; incidence of extensive cGVHD was 13.8%. So far, 1 case relapsed, 1 case displayed graft rejection, and poor function of graft occurred in 1 case, death occurred in 2 cases(6.7%). It is concluded that tumor-ablative chemotherapy combined with low intensity-modified BUCy/TBICy is safe and effective in allogeneic hematopoietic stem cell transplantation for hematologic malignancies, and it is useful to reduce relapse of hematologic malignancies after transplantation.
